Zacks: Brokerages Anticipate Ascendis Pharma A/S (NASDAQ:ASND) to Post -$2.63 EPS

Wall Street analysts expect that Ascendis Pharma A/S (NASDAQ:ASND) will announce earnings per share (EPS) of ($2.63) for the current quarter, according to Zacks. Four analysts have issued estimates for Ascendis Pharma A/S’s earnings. The highest EPS estimate is ($2.16) and the lowest is ($3.05). Ascendis Pharma A/S posted earnings of ($3.15) per share during the same quarter last year, which would suggest a positive year over year growth rate of 16.5%. The company is expected to announce its next quarterly earnings results on Wednesday, March 9th.

On average, analysts expect that Ascendis Pharma A/S will report full-year earnings of ($8.43) per share for the current year, with EPS estimates ranging from ($9.57) to ($7.30). For the next financial year, analysts expect that the company will post earnings of ($9.35) per share, with EPS estimates ranging from ($11.10) to ($6.30). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Tuesday, November 9th. The biotechnology company reported ($1.47) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.60) by $1.13. Ascendis Pharma A/S had a negative return on equity of 50.72% and a negative net margin of 12,211.21%. The firm had revenue of $1.31 million for the quarter, compared to the consensus estimate of $1.60 million. During the same quarter last year, the business posted ($2.70) EPS.

ASND has been the topic of several recent research reports. Wedbush dropped their price target on Ascendis Pharma A/S from $191.00 to $186.00 in a research note on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Ascendis Pharma A/S in a research report on Thursday, November 18th. SVB Leerink lifted their target price on Ascendis Pharma A/S from $182.00 to $190.00 and gave the company an “outperform” rating in a research report on Monday, November 15th. Wells Fargo & Company began coverage on Ascendis Pharma A/S in a research report on Wednesday, December 8th. They issued an “overweight” rating and a $176.00 target price on the stock. Finally, Credit Suisse Group lowered their target price on Ascendis Pharma A/S from $185.00 to $179.00 and set an “outperform” rating on the stock in a research report on Thursday, November 11th. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $178.67.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Moors & Cabot Inc. acquired a new position in Ascendis Pharma A/S during the third quarter worth approximately $548,000. Janus Henderson Group PLC boosted its holdings in shares of Ascendis Pharma A/S by 4.0% during the third quarter. Janus Henderson Group PLC now owns 3,251,667 shares of the biotechnology company’s stock worth $518,306,000 after acquiring an additional 124,496 shares during the period. GQG Partners LLC bought a new stake in shares of Ascendis Pharma A/S during the third quarter worth approximately $438,000. Voloridge Investment Management LLC bought a new stake in shares of Ascendis Pharma A/S during the third quarter worth approximately $1,013,000. Finally, Wellington Management Group LLP boosted its holdings in shares of Ascendis Pharma A/S by 14.9% during the third quarter. Wellington Management Group LLP now owns 3,945,244 shares of the biotechnology company’s stock worth $628,832,000 after acquiring an additional 510,971 shares during the period.

ASND opened at $122.96 on Wednesday. The business’s 50-day moving average price is $139.01 and its two-hundred day moving average price is $141.40. Ascendis Pharma A/S has a 1 year low of $109.36 and a 1 year high of $178.71. The company has a market capitalization of $6.99 billion, a price-to-earnings ratio of -13.22 and a beta of 0.72.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Further Reading: What is Cost of Capital?

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.